PROJENX

ProJenX is a clinical-stage biotechnology company with novel, brain-penetrant, targeted therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and researchers at Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS... ProJenX spun out of a long-term collaboration between the ALS research nonprofit, Project ALS, and researchers at Columbia University, who have worked together for over twenty years toward a shared goal of developing the first effective treatments, and ultimately a cure, for ALS... ProJenX's mission is to make prosetin, a scientifically validated, first-in-class MAP4 kinase inhibitor, available for ALS and other neurodegenerative diseases.

Primary location: Eric United States